Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS) (2022)
Attributed to:
University of Oxford – Confidence in Concept 2019
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Type: Conference/Paper/Proceeding/Abstract
Volume: 22
Parent Publication: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
ISSN: 2152-2650